The DOI matches its Crossref record; 489 of the 506 references it cites were found in a registry or an index.
RAF-MEK-ERK pathway in cancer evolution and treatment
Abstract
The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway involved in cell proliferation and survival. The three-layered MAPK signaling cascade is initiated upon RTK and RAS activation. Three RAF isoforms ARAF, BRAF and CRAF, and their downstream MEK1/2 and ERK1/2 kinases constitute a coherently orchestrated signaling module that directs a range of physiological functions. Genetic alterations in this pathway are among the most prevalent in human cancers, which consist of numerous hot-spot mutations such as BRAF V600E. Oncogenic mutations in this pathway often override otherwise tightly regulated checkpoints to open the door for uncontrolled cell growth and neoplasia. The crosstalk between the RAF-MEK-ERK axis and other signaling pathways further extends the proliferative potential of this pathway in human cancers. In this review, we summarize the molecular architecture and physiological functions of the RAF-MEK-ERK pathway with emphasis on its dysregulations in human cancers, as well as the efforts made to target the RAF-MEK-ERK module using small molecule inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activated RAS proteins can interact with many downstream effector proteins, such as RAF kinase, son of sevenless (SOS), phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide dissociation stimulating factors (RalGDS), which regulate cell events such as cell proliferation and apoptosis.323–325”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [325]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
AMPK: guardian of metabolism and mitochondrial homeostasis
Herzig, S., & Shaw, R. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.95 · Cited by 4,192
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G. W., Robinson, F. L., Gibson, T. B., Xu, B.-E., Karandikar, M. S., Berman, K. S., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,111
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Flagged first, then by citations
17 of the 506 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Pagès, 1999, Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice, Science, 286, 1374, 10.1126/science.286.5443.1374 · DOI · Paper page
Cited by
Sorted by citations
Items 501–557 of 557
Li, J., Du, F., Ji, Y., Wang, H., Zhu, D., Zhou, W., Chen, N., Dai, L., Fang, C., Liu, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102265
Zhan, L.-Y., Zhe-ling, C., & Yang, L. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-025-01520-0
“Sign-aling through the RAS-RAF-MEK-ERK pathway is initiated by the binding of multiple ligands to RTK, including the epidermal growth factor receptor (EGFR), and targeting components of this pathway is an attractive target for the development of potential anticancer therapies [37, 38].”
Polymeric Gene Delivery Systems: Design Principles for Targeting Oncogenic Pathways
Jahanbekam, S., Aldhafeeri, B., Alipour, S., & Varamini, P. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00085
You, S., Li, C., Sun, W., Wang, X., Huang, L., Li, L., Weiqiang, G. U. O., Xiang, M., & Zhou, L. (2026) · Carcinogenesis · doi:10.1093/carcin/bgag038
Li, D., Yang, H., Feng, Y., Liu, X., Wang, F., Jiang, Y., 吴素琴, & Mei, X. (2026) · Mediators of Inflammation · doi:10.1155/mi/7413982
“The RAF-MEK-ERK cascade, in particular, is essential for regulating these processes and has been implicated in the development of RA [16], as well as in the modulation of FLSs proliferation and in fl ammatory responses [17, 18].”
Effects of ERK1/2 Signaling on Cell Cycle Regulation by the Tuberin-Cyclin B1 ComplexPreprint
Pillon, A., Nadi, A., Martin, J., Hanna, M. A., da Silva, E. F., & Porter, L. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.03.729845
“The implications of mutations in the ERK pathway are numerous and can be attributed to the many interacting partners found downstream of ERK activation [27].”
Liao, C., Zhu, X., Yang, Y., Zhu, J., Liu, X., Tang, M., Luo, M., Zhong, X., Xu, L., Liao, H., et al. (2026) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2026064579
Zhang, Y., Li, Y., Li, N., Zou, C., Liu, C., Zhang, X., Ding, X., Cao, R., Liu, L., Ran, X., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113284
Abdulmonem, M. R., Mahdi, M. F., & Raauf, A. M. R. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e186971
Cancer Signaling Pathways and Cancer Biology
Nair, A., Prasad, A. P., Anand, A. V., Shyl, D., & Yesupatham, S. K. (2026) · Studies in Rhythm Engineering · doi:10.1007/978-981-95-8938-8_7
Mapping the interactome of recombinant human protein KIAA1143
Wang, R., Feng, X., & Xie, Y. (2026) · Protein Expression and Purification · doi:10.1016/j.pep.2026.106972
Wang, R., Li, X., Zhang, T., Chen, Y., Liu, J., Wang, Y., Wang, X., Cao, L., Lu, Z., & Ma, L. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113332
Mo, L., Yu, F., Peng, M., He, Y., Xie, S., Wu, S., Zhang, Z., Wang, C., Zhao, W., Ouyang, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1860873
“According to our network enrichment analysis, the affected targets are significantly enriched in the ERK signaling pathway, focal adhesions, and chemical carcinogenesis pathways, providing a molecular basis for the malignant transformation induced by AAI (Eke and Cordes, 2015; Ullah et al., 2022).”
Current Molecular-Targeted Therapies in Melanoma and Their Mechanism of Resistance
Bahari, R., Nguyen, M., Sohail, N., Lopez, S., Vasanthi, S. S., Amin, J., Ramaswami, D., Kapetaneas, G., Karne, R., Altayeh, U., et al. (2026) · Cancers · doi:10.3390/cancers18142310
“Several MEK inhibitors have demonstrated clinical efficacy in advanced melanoma, including trametinib, cobimetinib, and binimetinib [45].”
Yin, Q., Gu, J., Bai, R., Zhao, K., Wang, Q. Q., Liu, Y., Liu, Y., & Li, H. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1836521
“This is a common observation in network pharmacology studies and does not indicate that PQs are carcinogenic (Ullah et al., 2022; Zhou et al., 2022).”
Self-citationDrugging ERK1/2 in Cancer: A Glimpse of Small‐Molecule Inhibitors
Peng, Z., Fu, Y., Chen, Y., Fan, B., & Liu, B. (2026) · Medicinal Research Reviews · doi:10.1002/med.70084
New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer
Takahashi, M., Taniguchi, S. H., & Yoshida, Y. (2026) · Cancer Science · doi:10.1111/cas.70480
“…mutations, the main one of which is BRAF V600E , first activate BRAF, which results in the activation of mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) through their phosphorylation, leading to greater growth and survival of cancer cells [3, 4].”
Cancer Cells, Oncogenes, and Therapeutic Interventions
Minden, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-20529-2_19
Zhang, Y., Lu, W., Hu, L., Huang, Z., Lin, W., Guo, D., & Liu, Z. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10252-6
“Functional validation confirmed that itRF-GlnCTG induces a shift in EMT markers and suppresses the phosphorylation of p38 and ERK, indicating an inhibitory effect on the MAPK signaling cascade, a critical driver of tumor progression (Ullah et al. 2022).”
Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment
Chen, X., & Wang, Z. (2026) · Cancers · doi:10.3390/cancers18152451
“Ras-Erk pathways influence cell behavior by activating transcription factors in the nucleus either directly or indirectly via cytosolic substrates like RSK and MNK. Key transcription factors involved include Jun, Fos, SRF, Elk-1, Myc, STAT3, and MSK [38] (Figure 2).”
Molecular basis of mitogen-activated protein kinase ERK2 activation by its upstream kinase MEK1Preprint
von Velsen, J., Juyoux, P., Piasentin, N., Fisher, H., Lapouge, K., Vadas, O., Gervasio, F. L., & Bowler, M. W. (2026) · eLife · doi:10.7554/elife.111925
Molecular basis of mitogen-activated protein kinase ERK2 activation by its upstream kinase MEK1Preprint
von Velsen, J., Juyoux, P., Piasentin, N., Fisher, H., Lapouge, K., Vadas, O., Gervasio, F. L., & Bowler, M. W. (2026) · eLife · doi:10.7554/elife.111925.1
Harnessing the quinoline core for targeted cancer therapy
Liu, C., Huang, W.-W., Wang, J., Jiang, W.-S., Xin-yue, 张. Z., Chen, X., Gao, Y., & Dai, X. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2718761
Le, S., Le, Y., Sha, X., Qiu, F., & Zhang, L. (2026) · Cancer Science · doi:10.1111/cas.70496
“The RAS–RAF–MEK–ERK signaling cascade governs cell proliferation, differentiation, and survival, and its aberrant activation is a hallmark of many cancers, including lung cancer [29–31].”
Forsyth, A., Imokhai, O. P., Fure, K., do Valle, R., Ayoub, R., Sataray-Rodriguez, A., Martinez, G., & Brooks, A. E. (2026) · Biomedicines · doi:10.3390/biomedicines14081833
“NRAS Q61 mutations constitutively activate RAFs—predominantly CRAF—which phosphorylate MEK1/2, driving ERK-dependent transcription and melanocyte proliferation [3,26].”
InfluentialShang, W., Luo, H., Li, S., Yu, S., Wang, X., Fu, D., Wang, L., Meng, F., & Gao, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1892269
DUSP1 Inhibits Mechanotransduction and MAPK Signalling to Alleviate Myocardial Cell Hypertrophy
Zhong, X., Kong, L., Zhang, Y., Li, J., Guan, S., & Qu, X. (2026) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70152
Lu, J., Xuan, M., Yu, L., Xie, Z., Chu, Q., Wei, S., Wang, T., Xue, C., & Li, L. (2026) · MedComm · doi:10.1002/mco2.70994
Novel levoglucosenone derivatives: Preclinical evaluation in breast cancer models
Cañonero, L., Schey, A., Bareño, L. A. A., Bechis, A., Neira, D. B., Cámpora, F., Pava-Gómez, B. E., Sarotti, A. M., Suárez, A. G., Mangione, M. I., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179346
A sensitive interactome-based approach to characterize drug activity in living human cells
Kundlacz, C., Forcet, C., Sleiman, N. H., VONAU, S., Marmigère, F., Gillet, B., Hughes, S., Gilquin, L., Duplus‐Bottin, H., Dumont, A., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113557
“The majority of these inhibitors primarily target RAF, but their therapeutic application is limited by the observation of MAPK signaling reactivation and cancer resistance post-treatment (5, 6).”
Liu, D., Xie, D., Che, X., Li, X., Xu, W., & Wu, G. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108456
Targeted therapy for brain tumors: overview and application to precision medicine
Newton, H. B., & Allen, B. C. (2026) · Exploration of neuroscience · doi:10.37349/en.2026.1006150
Yamamoto, R., Hosogi, S., Toda, Y., Shiozaki, A., & Ashihara, E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1889708
“These observations may be consistent with differential changes in Akt and ERK1/2 signaling under extracellular acidosis; however, the functional signi fi cance of these changes for cell survival and proliferation remains uncertain (35 – 37).”
González-Seguel, C., Quiroga, J., Hancke, J. L., Ehrenfeld, P., Barrales, P., & Burgos, R. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1921579
“…phosphorylations of MAPK kinase kinase (MAPKKK) and MAPK kinase (MAPKK), culminating in the phosphorylation of one of the main families, such as extracellular signal-regulated kinases (ERK), JNKs, and p38/MAPK, and has been found to be dysregulated in various cancer types (Ullah et al., 2022).”
Cutaneous reactions to modern systemic oncologic therapies: a histopathological and clinical review
Maciel, E. S., Kersh, A. E., & Chu, E. Y. (2026) · Histopathology · doi:10.1111/his.70286
Dimitrakopoulou, M.-E., Theocharopoulos, C., Katsandri, A., Foteinou, D., Stefanou, D. T., Gkoufa, A., Tsoukalas, K., Bousou, T., Anastasopoulou, A. N., Gogas, H., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105630
Liu, K.-Y., Zhao, X., Liu, J., Li, M.-N., Cui, H., Wang, Z., & Zhou, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1951750
“Aberrant activation of receptor tyrosine kinases (RTKs) and their downstream signaling cascades, including the PI3K-AKT-mTOR and MAPK pathways, is a key driver of tumorigenesis and tumor progression (He et al., 2021; Ullah et al., 2022; Tomuleasa et al., 2024).”
Liu, T., Li, B., Lan, F., Huang, J., 叶玉勤, & Su, X. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin52923
Abdelrahman, A. H. M., Ali, S. S. M., Attia, M. A. A., Sidhom, P. A., Han, Y., Hussien, T. A., Ibrahim, M. A. A., & El‐Tayeb, M. A. (2026) · Chemical Physics · doi:10.1016/j.chemphys.2026.113522
Zhou, Y., Fan, K., Cheng, X., Haseeb, A., Noor, F., Sun, N., Yin, W. H., Yang, H., Sun, P., Zhang, H., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154724
Identification of PAK Gene Fusions in an Ovarian and a Testicular Serous Carcinoma
Khorsandi, N., Simko, J., Devine, W. P., Gasper, C., & Sirohi, D. (2026) · International Journal of Surgical Pathology · doi:10.1177/10668969261482144
Xu, J., Zuo, Y., Zhang, T., He, Y., Long, T., Jiao, M., Lu, R., Xiong, K., & Chen, Y. (2025) · Advanced technology in neuroscience . · doi:10.4103/atn.atn-d-25-00022
Pathway-scale variant effect mapping reveals the importance of cell contextPreprint
Simon, J. J., Pendyala, S., Adebanjo, A. F., Holmes, D. L., Walsh, M., Vandi, A. J., Wang, Z. R., Wheelock, M. K., Opsahl, J. L., Shihora, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.04.756099
Zeng, Y., Lyu, L., 卢羽洁, Wang, C., Mu, M., & Zhang, X. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120924
In silico design of novel indolinone-based anticancer agents and proposal of synthetic routes
Er-rajy, M., fadili, M. E., Etabti, H., Aziz, A., Lenda, F., Mujwar, S., Chtita, S., Samadi, A., & Elhallaoui, M. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1964610
“Because cancer cells can change and tumor signaling is complex, treatment often needs more than one approach, such as combining therapies or trying alternative options, to reduce resistance and improve patient outcomes (Lim et al., 2017; Ullah et al., 2022).”
FAM43B mediates BMAL1-driven regulation of ERK signaling to promote cervical cancer progression
Pan, C., & Li, M. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-11008-6
“Abnormal cascade phosphorylation activation continuously promotes cancer cell proliferation, cell cycle disorder, colony formation, migration and invasion, serving as a canonical driving pathway for cervical cancer progression (Ullah et al. 2022, Klomp et al. 2024).”
Yang, H., Huang, C., Wang, H., & Chen, L. (2026) · iScience · doi:10.1016/j.isci.2026.117882
“31 Despite a robust upregulation of p -ERK1/2, no significant increase in p -SMAD1/5/8/9 was detected following BMP2 overexpression (Figure 8).”
Ras/MAPK Pathway in Viral Associated Cancers
Rafiei, F., Goudarzi, H., Tavakolian, S., Gourabi, M. J. R., & Faghihloo, E. (2026) · Archives of Razi Institute · doi:10.66224/ari.81.3.3413
“Raf activation requires direct interaction with GTP-bound RAS, which facilitates dephosphorylation and dimerization of Raf proteins, leading to the conformational changes necessary for Raf activation [63, 64].”
InfluentialFunctional stratification of YWHAZ variants explains distinct neurodevelopmental disorders
Popov, I. K., Motta, M., Prandi, I. G., Tao, J., Priolo, M., Ferilli, M., Jamra, R. A., Balton, E. V., Banneau, G., Bruselles, A., et al. (2026) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2026.10.001
Recent Therapeutic Improvements in Pediatric Oncology: One Fellow Generation (2020–2025)
Quintero-García, D., Seguí, A., Palau, A. G., Pablos, A., Nadal, M., Vega, A. I., Bueno, I., Cañada, M. D., Suarez, R. P., Iriondo, M., et al. (2026) · Cancers · doi:10.3390/cancers18213447
Chae, B. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219598
Kurowska, K., Borczyk, M., Łukasiewicz, K., & Podlewska, S. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109636
Metadata
- Authors
- Ullah, R., Yin, Q., Snell, A. H., & Wan, L.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Wan, Lixin
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 85
- Pages
- 123-154
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W3160873367
- Cited by
- 553
- References
- 506
- Citations by year
- 2026: 123 · 2025: 164 · 2024: 173 · 2023: 69 · 2022: 19
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Seminars in Cancer Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Melanoma Research Alliance
- Florida Department of Health
- American Cancer Society
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Raf/MEK/ERK pathway, MAPK signaling, BRAF V600E mutation, Raf isoforms, MEK1/2, ERK1/2, Ras activation, receptor tyrosine kinase signaling, tumor evolution, cancer therapy, small molecule inhibitors, signaling crosstalk, oncogenic mutations
- MeSH terms
- Humans, Neoplasms, Signal Transduction, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
